Highlights and Vision
A snapshot of the Knight Cancer Institute

To begin with...
Beat AML® Master Clinical Trial is the first collaborative precision medicine clinical trial in a blood cancer. The trial uses advanced genomic technology to identify each patient’s cancer-driving genetic mutations, and then matches patients to the targeted treatment.
• Investigational Multi-Cancer Early Detection Blood Test
• 6600 participants enrolled

FDA approved avapritinib for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
Sparing nerves during surgery
“This award will make it possible for us to reach out to veterans throughout Oregon and Southwest Washington to offer genetic testing and sequencing for all patients with metastatic prostate cancer.”
— Julie Graff, M.D.

Centers of Excellence

Jason A. Webb, M.D.
Flavio Rocha, M.D., F.A.C.S.

Molecular profiling, precision oncology
Data science
Biomarker

Early Detection

Thank You